ISS Recommends Aptose Biosciences Shareholders Vote 'FOR' Hanmi Pharmaceutical Acquisition

summarizeSummary

Aptose Biosciences announced that ISS recommends shareholders vote 'FOR' the acquisition by Hanmi Pharmaceutical, a key step towards closing the C$2.41 per share cash deal.

check_boxKey Events

• ISS Recommends Acquisition Approval

  Institutional Shareholder Services (ISS) has recommended that Aptose shareholders vote 'FOR' the special resolution to approve the Plan of Arrangement with Hanmi Pharmaceutical Co. Ltd.

• Acquisition Terms Confirmed

  Upon completion, shareholders will receive C$2.41 in cash per common share, representing a 28% premium over the 30-day VWAP of C$1.88 on the TSX as of November 19, 2025.

• Shareholder Meeting Reconvened

  A special meeting of shareholders to approve the Arrangement and a Continuance (change of incorporation) has been reconvened to March 31, 2026, following a postponement to address SEC comments.

• Board Unanimously Recommends 'FOR'

  Aptose's board of directors unanimously recommends that shareholders vote 'FOR' both the Continuance and the Arrangement Resolution.

auto_awesomeAnalysis

Institutional Shareholder Services (ISS), a leading independent proxy advisory firm, has recommended that Aptose shareholders approve the proposed Plan of Arrangement with Hanmi Pharmaceutical. This recommendation significantly increases the likelihood of the acquisition closing, as ISS guidance often sways institutional investors. The deal offers C$2.41 in cash per share, representing a 28% premium over the 30-day VWAP as of November 2025, providing liquidity and certainty of value to shareholders. The reconvened shareholder meeting on March 31, 2026, is the next critical step for the transaction's completion.